Mark D. Booth
2012
In 2012, Mark D. Booth earned a total compensation of $1.2M as Chief Commercial Officer outgoing at Orexigen Therapeutics, a 27% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $185,493 |
|---|---|
| Option Awards | $736,099 |
| Salary | $285,374 |
| Other | $7,776 |
| Total | $1,214,742 |
Booth received $736.1K in option awards, accounting for 61% of the total pay in 2012.
Booth also received $185.5K in non-equity incentive plan, $285.4K in salary and $7.8K in other compensation.
Rankings
In 2012, Mark D. Booth's compensation ranked 5,390th out of 11,487 executives tracked by ExecPay. In other words, Booth earned more than 53.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,390 out of 11,487 | 53rd |
Division Manufacturing | 1,895 out of 4,253 | 55th |
Major group Chemicals And Allied Products | 458 out of 1,198 | 62nd |
Industry group Drugs | 302 out of 920 | 67th |
Industry Pharmaceutical Preparations | 236 out of 700 | 66th |
Source: SEC filing on April 22, 2015.
Booth's colleagues
We found four more compensation records of executives who worked with Mark D. Booth at Orexigen Therapeutics in 2012.
2012
Michael Narachi
Orexigen Therapeutics
Chief Executive Officer
2012
Preston Klassen
Orexigen Therapeutics
Head of Global Contrave Program and Executive Vice President, Product Development
2012
Joseph Hagan
Orexigen Therapeutics
Chief Business and Financial Officer
2012
Heather Turner
Orexigen Therapeutics